In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients with presbyopia for up to eight hours. The top-line results come f ...
LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce today the completion of their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback